Citadel Advisors
RKDA icon

Citadel Advisors’s Arcadia Biosciences RKDA Stock Holding History

Citadel Advisors’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13
Closed -$136 – 15392
2022
Q4 		$136 Buy
+13
New +$185 ﹤0.01% 14752
2021
Q4 		– Sell
-393
Closed -$33K – 14599
2021
Q3 		$33K Sell
393
-208
-35% -$19.5K ﹤0.01% 13542
2021
Q2 		$71K Sell
601
-110
-15% -$12K ﹤0.01% 13156
2021
Q1 		$78K Buy
+711
New +$87.2K ﹤0.01% 12651

Other funds holding RKDA

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BWM
Bullock Wealth Management Bloomington, Indiana $231M AUM
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citadel Advisors's RKDA Position: Q2 2026 in Review

Citadel Advisors opened a new position in Arcadia Biosciences (RKDA) in Q2 2026: 23,738 shares worth $16.1K. The stake represents ﹤0.01% of the portfolio and ranks #13445 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in RKDA as recently as Q4 2022.

Citadel Advisors first reported a position in RKDA in Q3 2016 and has held it in 10 quarters since. The position peaked at $77K in Q3 2019. 18 funds tracked by Wall St. Rank hold RKDA as of Q2 2026.

  • Citadel Advisors held 23,738 shares of Arcadia Biosciences worth $16.1K as of Q2 2026.
  • Arcadia Biosciences was a new Citadel Advisors position in Q2 2026.
  • Arcadia Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13445 holding.
  • Citadel Advisors first reported a position in Arcadia Biosciences in Q3 2016 and has held it in 10 quarters since.
  • Citadel Advisors's Arcadia Biosciences position peaked at $77K in Q3 2019.
  • 18 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.